Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

404 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial.
Hagel S, Bach F, Brenner T, Bracht H, Brinkmann A, Annecke T, Hohn A, Weigand M, Michels G, Kluge S, Nierhaus A, Jarczak D, König C, Weismann D, Frey O, Witzke D, Müller C, Bauer M, Kiehntopf M, Neugebauer S, Lehmann T, Roberts JA, Pletz MW; TARGET Trial Investigators. Hagel S, et al. Among authors: pletz mw. Intensive Care Med. 2022 Mar;48(3):311-321. doi: 10.1007/s00134-021-06609-6. Epub 2022 Feb 1. Intensive Care Med. 2022. PMID: 35106617 Free PMC article. Clinical Trial.
Therapeutic drug monitoring-based dose optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial.
Hagel S, Fiedler S, Hohn A, Brinkmann A, Frey OR, Hoyer H, Schlattmann P, Kiehntopf M, Roberts JA, Pletz MW; TARGET Study Group. Hagel S, et al. Among authors: pletz mw. Trials. 2019 Jun 6;20(1):330. doi: 10.1186/s13063-019-3437-x. Trials. 2019. PMID: 31171029 Free PMC article.
Correction to: Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial.
Hagel S, Bach F, Brenner T, Bracht H, Brinkmann A, Annecke T, Hohn A, Weigand MA, Michels G, Kluge S, Nierhaus A, Jarczak D, König C, Weismann D, Frey O, Witzke D, Müller C, Bauer M, Kiehntopf M, Neugebauer S, Lehmann T, Roberts JA, Pletz MW; TARGET Trial Investigators. Hagel S, et al. Among authors: pletz mw. Intensive Care Med. 2022 May;48(5):646-647. doi: 10.1007/s00134-022-06668-3. Intensive Care Med. 2022. PMID: 35303118 Free PMC article. No abstract available.
Another trial for the TARGET trial. Author's reply.
Hagel S, Pletz MW, Lehmann T. Hagel S, et al. Among authors: pletz mw. Intensive Care Med. 2022 Jun;48(6):776-777. doi: 10.1007/s00134-022-06670-9. Epub 2022 Mar 23. Intensive Care Med. 2022. PMID: 35320369 Free PMC article. No abstract available.
[Bacteremia and sepsis].
Hagel S, Pletz MW, Brunkhorst FM, Seifert H, Kern WV. Hagel S, et al. Among authors: pletz mw. Internist (Berl). 2013 Apr;54(4):399-407. doi: 10.1007/s00108-012-3185-4. Internist (Berl). 2013. PMID: 23478795 German.
[Management of community acquired pneumonia].
Hagel S, Moeser A, Pletz MW. Hagel S, et al. Among authors: pletz mw. MMW Fortschr Med. 2018 Nov;160(19):52-61. doi: 10.1007/s15006-018-0027-x. MMW Fortschr Med. 2018. PMID: 30406515 Review. German. No abstract available.
Population pharmacokinetics and probability of target attainment in patients with sepsis under renal replacement therapy receiving continuous infusion of meropenem: Sustained low-efficiency dialysis and continuous veno-venous haemodialysis.
Westermann I, Gastine S, Müller C, Rudolph W, Peters F, Bloos F, Pletz M, Hagel S. Westermann I, et al. Br J Clin Pharmacol. 2021 Nov;87(11):4293-4303. doi: 10.1111/bcp.14846. Epub 2021 May 4. Br J Clin Pharmacol. 2021. PMID: 33818823 Free article.
Who benefits from antimicrobial combination therapy?
Pletz MW, Hagel S, Forstner C. Pletz MW, et al. Lancet Infect Dis. 2017 Jul;17(7):677-678. doi: 10.1016/S1473-3099(17)30233-5. Epub 2017 Apr 22. Lancet Infect Dis. 2017. PMID: 28442294 No abstract available.
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.
Arabi YM, Gordon AC, Derde LPG, Nichol AD, Murthy S, Beidh FA, Annane D, Swaidan LA, Beane A, Beasley R, Berry LR, Bhimani Z, Bonten MJM, Bradbury CA, Brunkhorst FM, Buxton M, Buzgau A, Cheng A, De Jong M, Detry MA, Duffy EJ, Estcourt LJ, Fitzgerald M, Fowler R, Girard TD, Goligher EC, Goossens H, Haniffa R, Higgins AM, Hills TE, Horvat CM, Huang DT, King AJ, Lamontagne F, Lawler PR, Lewis R, Linstrum K, Litton E, Lorenzi E, Malakouti S, McAuley DF, McGlothlin A, Mcguinness S, McVerry BJ, Montgomery SK, Morpeth SC, Mouncey PR, Orr K, Parke R, Parker JC, Patanwala AE, Rowan KM, Santos MS, Saunders CT, Seymour CW, Shankar-Hari M, Tong SYC, Turgeon AF, Turner AM, Van de Veerdonk FL, Zarychanski R, Green C, Berry S, Marshall JC, McArthur C, Angus DC, Webb SA; REMAP-CAP Investigators. Arabi YM, et al. Intensive Care Med. 2021 Aug;47(8):867-886. doi: 10.1007/s00134-021-06448-5. Epub 2021 Jul 12. Intensive Care Med. 2021. PMID: 34251506 Free PMC article. Clinical Trial.
404 results